Ovid Therapeutics OVID
2.40
(0.10)
(4.00%)
as of 25 Sep
- Market cap
- $487.3M
- P/E
- 0.0×
Follow OVID
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 1.81 | 0.00 | — | — | — | — |
P/S ratio |
16.57 | 116.51 | 597.77 | 0.65 | 0.00 | 0.00 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 1.83 | 0.00 | — | — | — | — |
P/Operating CF |
(11.55) | (6.59) | (19.67) | (14.89) | (18.05) | (9.31) | — | — | — | — |
P/B ratio |
0.92 | 0.97 | 2.67 | 1.03 | 1.21 | 3.09 | — | — | — | — |
Price to Tangible BV |
0.92 | 0.97 | 2.68 | 1.03 | 1.21 | 3.12 | — | — | — | — |
EV/Sales |
8.62 | 46.44 | 365.43 | 0.11 | 0.00 | 0.00 | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.23 | 0.00 | — | — | — | — |
EV/Operating CF |
(1.63) | (0.47) | (3.13) | (0.43) | 0.24 | (1.22) | — | — | — | — |
EV/FCF |
(1.63) | (0.47) | (3.12) | (0.42) | 0.24 | (1.21) | — | — | — | — |
Quick Ratio |
8.40 | 5.04 | 9.22 | 18.45 | 12.69 | 3.27 | 7.39 | 4.76 | 14.47 | 13.91 |
Current Ratio |
8.97 | 5.32 | 9.55 | 18.79 | 12.87 | 3.39 | 7.58 | 5.01 | 14.71 | 14.04 |
Net Debt/EBITDA |
1.37 | 0.65 | 1.55 | 2.09 | (1.51) | 0.89 | 1.25 | 0.79 | 1.34 | 2.31 |
Debt/Assets |
7.94% | 14.56% | 10.25% | 10.31% | 0.00% | 0.08% | 0.35% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.09 | 0.20 | 0.17 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.06 | 0.00 | 0.00 | 0.01 | 1.54 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
2.20 | 2.12 | 0.87 | 1.02 | 0.99 | 0.64 | 0.85 | 0.88 | 0.49 | 0.79 |
Capex/Depreciation |
0.00 | (0.26) | (0.24) | (1.03) | (0.80) | (1.27) | (0.96) | (2.48) | (0.59) | (3.35) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (17.51%) | (33.88%) | (47.57%) | (34.72%) | 107.30% | (142.60%) | (111.11%) | (85.04%) | (97.66%) | (38.20%) | |
| (14.33%) | (22.38%) | (34.98%) | (30.97%) | 88.61% | (103.38%) | (94.11%) | (75.82%) | (90.97%) | (36.33%) | |
ROIC |
(36.33%) | (135.38%) | 0.00% | (180.14%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(26.25%) | (57.65%) | (52.92%) | (43.15%) | 68.12% | (153.14%) | (87.19%) | (146.45%) | (78.44%) | (46.01%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.10 | 0.00 | 0.00 | — | 0.00 |
Research and Development Expense of Revenue |
352.76% | 6,495.94% | 7,292.86% | 1,638.28% | 22.53% | 502.63% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
332.45% | 4,537.81% | 7,929.85% | 2,158.28% | 17.87% | 242.77% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
66.29% | 1,108.83% | 1,858.42% | 436.33% | 2.43% | 59.64% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.45 | 0.49 | 0.23 | 0.79 | 0.81 | 0.32 | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 10.30 | 0.00 | — | — | — | — |
Earnings Yield |
(13.82%) | (40.86%) | (22.59%) | (39.69%) | 55.14% | (60.61%) | — | — | — | — |
Free Cash Flow Yield |
(32.02%) | (85.08%) | (19.57%) | (41.46%) | 54.64% | (38.49%) | — | — | — | — |
Revenue per Share |
0.10 | 0.01 | 0.01 | 0.02 | 3.09 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.52) | (0.79) | (0.65) | (0.78) | 1.76 | (0.88) | (1.30) | (1.85) | (1.63) | (1.81) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | 0.00 | (0.01) | (0.01) | (0.01) | 0.00 | (0.02) |
Free Cash Flow per Share |
(0.52) | (0.79) | (0.65) | (0.80) | 1.75 | (0.89) | (1.31) | (1.86) | (1.63) | (1.83) |
Cash per Share |
0.94 | 0.75 | 1.50 | 1.83 | 2.78 | 1.23 | 1.96 | 1.68 | 4.50 | 5.28 |
Shareholders Equity per Share |
1.77 | 0.96 | 1.24 | 1.88 | 2.66 | 0.75 | 1.79 | 1.58 | 4.31 | 5.01 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.77 | 0.96 | 1.24 | 1.88 | 2.66 | 0.75 | 1.79 | 1.58 | 4.31 | 5.01 |
Free Cash Flow |
(38.33) | (56.12) | (45.92) | (56.65) | 118.42 | (51.97) | (51.33) | (45.91) | (31.52) | (17.99) |
Working Capital |
66.08 | 45.42 | 98.13 | 124.39 | 175.68 | 52.78 | 69.28 | 35.42 | 82.57 | 48.68 |
Capital Expenditures |
— | (0.16) | (0.14) | (1.42) | (0.19) | (0.39) | (0.24) | (0.35) | (0.05) | (0.19) |
Net Current Asset Value |
54.09 | 32.00 | 53.37 | 108.39 | 175.68 | 42.55 | 68.99 | 35.42 | 82.57 | 48.68 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.23 | 0.00 | — | — | — | — |
Capex to Sales |
0.00 | 0.28 | 0.35 | 0.94 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
(240.13%) | (4,670.14%) | (13,351.79%) | (3,604.78%) | 57.51% | (642.26%) | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 1.74 | 0.00 | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.08 | 1.42 | 0.74 | 1.20 | 0.98 | 2.26 | 3.73 | 2.03 | 1.55 | 1.30 |
Cash ROIC |
(18.18%) | (41.86%) | (22.34%) | (20.33%) | 32.21% | (44.69%) | (34.79%) | (56.82%) | (18.48%) | (17.63%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.82 | 0.00 | 0.00 | — | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | — | — | 0.64 | 0.87 | 0.30 | — | 0.30 |
Average Payables |
2.57 | 3.45 | 2.83 | 4.54 | 6.29 | 4.35 | 3.51 | 2.89 | 1.44 | 0.76 |
Average Assets |
121.55 | 118.10 | 149.65 | 174.91 | 135.24 | 78.38 | 64.25 | 68.55 | 71.24 | 61.70 |
Average Common Equity |
99.44 | 78.01 | 110.04 | 156.01 | 111.69 | 56.83 | 54.41 | 61.12 | 66.36 | 58.67 |
Columns are period end dates